$KACLF
Kairous Acquisition Corp. Ltd Stock $kaclf

$kaclf Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-K Financial Statement

#000149315223034657 Filed on September 28, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2023
Revenue		$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$360.0K	$100.0K	$930.0K
YoY Change	83.38%	-7.76%	365.68%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$357.5K	$100.0K	$928.7K
YoY Change	82.1%	-7.76%	365.01%
Operating Profit	-$357.5K		-$928.7K
YoY Change	82.1%		365.01%
Interest Expense	$300.0K	$270.0K	$1.380M
YoY Change	-15.63%	153.78%	1104.71%
% of Operating Profit
Other Income/Expense, Net	$299.7K		$1.380M
YoY Change	-15.73%		1104.89%
Pretax Income	-$60.00K	$160.0K	$450.0K
YoY Change	-137.67%	-8060.2%	-628.36%
Income Tax
% Of Pretax Income
Net Earnings	-$57.82K	$160.0K	$451.5K
YoY Change	-136.3%	-8060.2%	-630.09%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.01		$0.07
Diluted Earnings Per Share	-$0.01	$0.04	$0.07
COMMON SHARES
Basic Shares Outstanding	4.436M shares	4.436M shares	6.876M shares
Diluted Shares Outstanding	4.436M shares		6.876M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$0.00	$40.00K	$40.00K
YoY Change	-100.0%	-91.72%	-91.72%
Cash & Equivalents	$3.150K	$39.36K
Short-Term Investments
Other Short-Term Assets	$40.00K	$70.00K	$70.00K
YoY Change	-58.28%	-36.43%	-36.43%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$45.06K	$112.2K	$110.0K
YoY Change	-89.69%	-81.09%	-81.45%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$23.46M	$22.80M	$22.80M
YoY Change	-70.4%	-71.1%	-71.1%
Other Assets		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Long-Term Assets	$23.46M	$22.80M	$22.80M
YoY Change	-70.4%	-71.11%	-71.11%
TOTAL ASSETS
Total Short-Term Assets	$45.06K	$112.2K	$110.0K
Total Long-Term Assets	$23.46M	$22.80M	$22.80M
Total Assets	$23.51M	$22.91M	$22.91M
YoY Change	-70.51%	-71.18%	-71.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$250.0K	$120.0K	$120.0K
YoY Change	282.44%	231.03%	231.03%
Accrued Expenses	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Deferred Revenue
YoY Change
Short-Term Debt	$1.780M	$1.260M	$1.260M
YoY Change	2442.86%	1700.0%	1700.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.034M	$1.384M	$1.380M
YoY Change	1252.67%	1041.14%	1038.14%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.730M	$2.730M	$2.730M
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Liabilities	$2.730M	$2.730M	$2.730M
YoY Change	0.0%	0.0%	0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.034M	$1.384M	$1.380M
Total Long-Term Liabilities	$2.730M	$2.730M	$2.730M
Total Liabilities	$4.764M	$4.114M	$4.110M
YoY Change	65.4%	44.27%	44.15%
SHAREHOLDERS EQUITY
Retained Earnings	-$4.719M	-$4.002M
YoY Change	94.26%	79.2%
Common Stock	$235.00	$235.00
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$4.719M	-$4.001M	$18.80M
YoY Change
Total Liabilities & Shareholders Equity	$23.51M	$22.91M	$22.91M
YoY Change	-70.51%	-71.18%	-71.19%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2023
OPERATING ACTIVITIES
Net Income	-$57.82K	$160.0K	$451.5K
YoY Change	-136.3%	-8060.2%	-630.09%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$198.2K	-$120.0K	-$778.6K
YoY Change	40.03%	130.72%	193.58%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$360.0K	-$120.0K	$57.47M
YoY Change			-172.95%
Cash From Investing Activities	-$360.0K	-$120.0K	$57.47M
YoY Change			-172.95%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$58.31M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$522.0K	150.0K	-$57.14M
YoY Change			-171.85%
NET CHANGE
Cash From Operating Activities	-$198.2K	-120.0K	-$778.6K
Cash From Investing Activities	-$360.0K	-120.0K	$57.47M
Cash From Financing Activities	$522.0K	150.0K	-$57.14M
Net Change In Cash	-$36.21K	-90.00K	-$443.6K
YoY Change	-74.42%	73.04%	-191.85%
FREE CASH FLOW
Cash From Operating Activities	-$198.2K	-$120.0K	-$778.6K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001865468
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023Q2	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent		usd
CY2023Q2	KACL	Accrued Offering Costs Current AccruedOfferingCostsCurrent		usd
CY2022Q2	us-gaap	Loans Payable Current LoansPayableCurrent		usd
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited		usd
CY2022	KACL	Cash Withdrawn From Trust Account In Connection With Redemption CashWithdrawnFromTrustAccountInConnectionWithRedemption		usd
CY2023	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2023	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock		usd
CY2022	us-gaap	Proceeds From Issuance Of Unsecured Debt ProceedsFromIssuanceOfUnsecuredDebt		usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations		usd
CY2023	KACL	Deferred Underwriters Commissions Charged To Additional Paidin Capital In Connection With Public Offering DeferredUnderwritersCommissionsChargedToAdditionalPaidinCapitalInConnectionWithPublicOffering		usd
CY2023	KACL	Remeasurement Adjustment Of Ordinary Shares To Redemption Value RemeasurementAdjustmentOfOrdinarySharesToRedemptionValue		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-41155
CY2023	dei	Entity Registrant Name EntityRegistrantName	KAIROUS ACQUISITION CORP. LIMITED
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	E9
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	Unit 9-3, Oval Tower @ Damansara
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	No. 685, Jalan Damansara
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	60000
CY2023	dei	Entity Address Address Line3 EntityAddressAddressLine3	Taman Tun Dr. Ismail
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Kuala Lumpur
CY2023	dei	Entity Address Country EntityAddressCountry	MY
CY2023	dei	City Area Code CityAreaCode	+603
CY2023	dei	Local Phone Number LocalPhoneNumber	7733 9340
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	true
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	4435959	shares
CY2023	dei	Auditor Firm AuditorFirmId	5395
CY2023	dei	Auditor Name AuditorName	Marcum Asia CPAs LLP
CY2023	dei	Auditor Location AuditorLocation	New York, NY
CY2023	dei	Auditor Firm AuditorFirmId	5395
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39359	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	482965	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	72810	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	110116	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	112169	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	593081	usd
CY2023Q2	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	22802239	usd
CY2022Q2	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	78894512	usd
CY2022Q2	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	25363	usd
CY2023Q2	us-gaap	Assets Assets	22914408	usd
CY2022Q2	us-gaap	Assets Assets	79512956	usd
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	123638	usd
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	36250	usd
CY2022Q2	KACL	Accrued Offering Costs Current AccruedOfferingCostsCurrent	15000	usd
CY2023Q2	us-gaap	Loans Payable Current LoansPayableCurrent	840000	usd
CY2023Q2	KACL	Working Capital Loans Sponsor WorkingCapitalLoansSponsor	420000	usd
CY2022Q2	KACL	Working Capital Loans Sponsor WorkingCapitalLoansSponsor	70000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1383638	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	121250	usd
CY2023Q2	KACL	Deferred Underwriting Commission Non Current DeferredUnderwritingCommissionNonCurrent	2730000	usd
CY2022Q2	KACL	Deferred Underwriting Commission Non Current DeferredUnderwritingCommissionNonCurrent	2730000	usd
CY2023Q2	us-gaap	Liabilities Liabilities	4113638	usd
CY2022Q2	us-gaap	Liabilities Liabilities	2851250	usd
CY2023Q2	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	2089816	shares
CY2022Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	7800000	shares
CY2023Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	22802239	usd
CY2022Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	78894512	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2346143	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2346143	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2346143	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2346143	shares
CY2023Q2	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares	2089816	shares
CY2022Q2	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares	7800000	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	235	usd
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	235	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4001704	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2233041	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-4001469	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-2232806	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22914408	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	79512956	usd
CY2023	us-gaap	Administrative Fees Expense AdministrativeFeesExpense	60000	usd
CY2022	us-gaap	Administrative Fees Expense AdministrativeFeesExpense	32833	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	868686	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	166881	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	928686	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	199714	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-928686	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-199714	usd
CY2023	us-gaap	Interest Income Other InterestIncomeOther	23	usd
CY2022	us-gaap	Interest Income Other InterestIncomeOther	34	usd
CY2023	us-gaap	Investment Income Net InvestmentIncomeNet	1380128	usd
CY2022	us-gaap	Investment Income Net InvestmentIncomeNet	114512	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1380151	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	114546	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	451465	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-85168	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6876476	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6876476	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6477792	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6477792	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6876476	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6477792	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.07
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.07
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.07
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	18695	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	7729883	usd
CY2022	KACL	Stock Issued During Period Value Sale Of Private Placement Units Net Of Allocated Offering Costs StockIssuedDuringPeriodValueSaleOfPrivatePlacementUnitsNetOfAllocatedOfferingCosts	3532263	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	341230	usd
CY2022	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	-13655197	usd
CY2022	KACL	Temporary Equity Remeasurement To Redemption Value Adjustment TemporaryEquityRemeasurementToRedemptionValueAdjustment	-114512	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-85168	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-2232806	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-2232806	usd
CY2023	KACL	Temporary Equity Remeasurement To Redemption Value Adjustment TemporaryEquityRemeasurementToRedemptionValueAdjustment	-2220128	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	451465	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	451465	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-4001469	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-4001469	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	451465	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-85168	usd
CY2023	us-gaap	Investment Income Net InvestmentIncomeNet	1380128	usd
CY2022	us-gaap	Investment Income Net InvestmentIncomeNet	114512	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-37306	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	105121	usd
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-25363	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	25363	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	87388	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	64951	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-778606	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-265213	usd
CY2023	KACL	Cash Deposited Into Trust Account CashDepositedIntoTrustAccount	840000	usd
CY2022	KACL	Cash Deposited Into Trust Account CashDepositedIntoTrustAccount	78780000	usd
CY2023	KACL	Cash Withdrawn From Trust Account In Connection With Redemption CashWithdrawnFromTrustAccountInConnectionWithRedemption	58312401	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	57472401	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-78780000	usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	76440100	usd
CY2022	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	3571430	usd
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	58312401	usd
CY2023	us-gaap	Proceeds From Issuance Of Unsecured Debt ProceedsFromIssuanceOfUnsecuredDebt	840000	usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	350000	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	70000	usd
CY2023	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	15000	usd
CY2022	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	553352	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-57137401	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	79528178	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-443606	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	482965	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	482965	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	39359	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	482965	usd
CY2023	KACL	Current Period Remeasurement Adjustment Of Ordinary Shares To Redemption Value CurrentPeriodRemeasurementAdjustmentOfOrdinarySharesToRedemptionValue	2220128	usd
CY2022	KACL	Current Period Remeasurement Adjustment Of Ordinary Shares To Redemption Value CurrentPeriodRemeasurementAdjustmentOfOrdinarySharesToRedemptionValue	114512	usd
CY2022	KACL	Deferred Underwriters Commissions Charged To Additional Paidin Capital In Connection With Public Offering DeferredUnderwritersCommissionsChargedToAdditionalPaidinCapitalInConnectionWithPublicOffering	2730000	usd
CY2022	KACL	Remeasurement Adjustment Of Ordinary Shares To Redemption Value RemeasurementAdjustmentOfOrdinarySharesToRedemptionValue	13655197	usd
CY2021Q4	us-gaap	Noninterest Expense Offering Cost NoninterestExpenseOfferingCost	4843252	usd
CY2021Q4	us-gaap	Payments For Underwriting Expense PaymentsForUnderwritingExpense	1559900	usd
CY2021Q4	us-gaap	Other Underwriting Expense OtherUnderwritingExpense	2730000	usd
CY2021Q4	KACL	Other Offering Costs OtherOfferingCosts	553352	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	2730000	usd
CY2023	KACL	Condition For Future Business Combination Use Of Proceeds Percentage ConditionForFutureBusinessCombinationUseOfProceedsPercentage	0.80	pure
CY2023	KACL	Condition For Future Business Combination Threshold Percentage Ownership ConditionForFutureBusinessCombinationThresholdPercentageOwnership	0.50	pure
CY2023	KACL	Threshold Percentage Of Public Shares Subject To Redemption Without Companys Prior Written Consent ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent	0.15	pure
CY2023	KACL	Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination	1	pure
CY2023	KACL	Redemption Period Upon Closure RedemptionPeriodUponClosure	P12M
CY2023	KACL	Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination	1	pure
CY2023	KACL	Maximum Net Interest To Pay Dissolution Expenses MaximumNetInterestToPayDissolutionExpenses	50000	usd
CY2023Q2	KACL	Working Capital Deficit WorkingCapitalDeficit	1271469	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39359	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84A_eus-gaap--UseOfEstimates_zsRjYecX351j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_z91MYjYkLWS7">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q2	us-gaap	Cash Cash	39359	usd
CY2022Q2	us-gaap	Cash Cash	482965	usd
CY2023Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2023Q2	us-gaap	Assets Held In Trust AssetsHeldInTrust	22800000	usd
CY2022Q2	us-gaap	Assets Held In Trust AssetsHeldInTrust	78900000	usd
CY2023	KACL	Offering Costs Associated With Initial Public Offering OfferingCostsAssociatedWithInitialPublicOffering	<p id="xdx_842_ecustom--OfferingCostsAssociatedWithInitialPublicOffering_zaAiyozvYqii" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zMFXt9PNm71l">Offering Costs associated with the Initial Public Offering</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company complies with the requirements of the Financial Accounting Standards Board (“FASB”) ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (“SAB”) Topic 5A, <i>“Expenses of Offering.”</i> Offering costs of $<span id="xdx_908_eus-gaap--OperatingCostsAndExpenses_c20220701__20230630__us-gaap--IncomeStatementLocationAxis__custom--OtherCostMember_zzq1pAyYpCld" title="Transaction costs">894,582</span> consisted principally of costs incurred in connection with preparation for the Initial Public Offering. These offering costs, together with the underwriter fees of $<span id="xdx_90C_ecustom--UnderwriterFee_c20220701__20230630_zEs1aFdWKHNg" title="Underwriter fees">4,289,900</span> (or $<span id="xdx_902_eus-gaap--PaymentsForUnderwritingExpense_c20220701__20230630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zwB9EMUxJzhc" title="Underwriting fees">1,559,900</span> paid in cash upon the closing of the Initial Public Offering and a deferred fee of $<span id="xdx_904_eus-gaap--OtherUnderwritingExpense_c20220701__20230630__us-gaap--SubsidiarySaleOfStockAxis__custom--DeferredUnderwritingCommissionsMember_zhsOLg9aJKJ9" title="Deferred underwriter fees">2,730,000</span>), were charged to stockholders’ equity upon completion of the Initial Public Offering.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>
CY2023	KACL	Underwriter Fee UnderwriterFee	4289900	usd
CY2023Q2	KACL	Working Capital Loans Sponsor WorkingCapitalLoansSponsor	420000	usd
CY2023Q2	KACL	Extension Loans ExtensionLoans	840000	usd
CY2023	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	5710184	shares
CY2023	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	58312401	usd
CY2023Q2	KACL	Temporary Equity Subject To Possible Redemption TemporaryEquitySubjectToPossibleRedemption	2089816	shares
CY2022Q2	KACL	Temporary Equity Subject To Possible Redemption TemporaryEquitySubjectToPossibleRedemption	7800000	shares
CY2023Q2	KACL	Temporary Equity Carrying Amount TemporaryEquityCarryingAmount	22802239	usd
CY2022Q2	KACL	Temporary Equity Carrying Amount TemporaryEquityCarryingAmount	78894512	usd
CY2023	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	5710184	shares
CY2023Q2	KACL	Redemption Of Ordinary Share RedemptionOfOrdinaryShare	-58312401	usd
CY2023Q2	KACL	Shares Subject To Mandatory Redemption Settlement Terms Shares SharesSubjectToMandatoryRedemptionSettlementTermsShares	2089816	shares
CY2022Q2	KACL	Shares Subject To Mandatory Redemption Settlement Terms Shares SharesSubjectToMandatoryRedemptionSettlementTermsShares	7800000	shares
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_zw3Ex2rPwSOd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zEEgBAA7MOa6">Concentration of Credit Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account. The Company has not experienced any losses on the Trust Account.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2346143	shares
CY2023Q2	KACL	Working Capital Loans Sponsor WorkingCapitalLoansSponsor	420000	usd
CY2022Q2	KACL	Working Capital Loans Sponsor WorkingCapitalLoansSponsor	70000	usd
CY2023Q2	KACL	Extension Loans ExtensionLoans	840000	usd
CY2022Q2	KACL	Extension Loans ExtensionLoans	0	usd
CY2023Q2	KACL	Business Combination Ordinary Price Per Share BusinessCombinationOrdinaryPricePerShare	10.10
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1125000	shares
CY2023	KACL	Percentage Of Underwriting Discountfee PercentageOfUnderwritingDiscountfee	0.20
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1725000	usd
CY2023	KACL	Deferred Fees Per Share DeferredFeesPerShare	0.35
CY2023	us-gaap	Payments For Underwriting Expense PaymentsForUnderwritingExpense	59900	usd
CY2023	KACL	Deferred Purchase Fee DeferredPurchaseFee	100	usd
CY2023	KACL	Deferred Underwriting Fee DeferredUnderwritingFee	105000	usd
CY2023	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	39000	shares
CY2023	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	341230	usd
CY2022Q4	us-gaap	Other Underwriting Expense OtherUnderwritingExpense	2730000	usd
CY2022Q4	us-gaap	Assets Held In Trust AssetsHeldInTrust	2000000	usd
CY2022Q4	us-gaap	Other Underwriting Expense OtherUnderwritingExpense	2730000	usd
CY2022Q4	us-gaap	Share Price SharePrice	10.00
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023	us-gaap	Common Stock Voting Rights CommonStockVotingRights	Holders of ordinary shares are entitled to one vote for each share
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2346143	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2346143	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2346143	shares
CY2023	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	5710184	shares
CY2023	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	58312401	usd
CY2023	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Description SharesSubjectToMandatoryRedemptionSettlementTermsDescription	if, and only if, the reported last sale price of the ordinary shares equals or exceeds $16.50 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations), for any 20 trading days within a 30-trading day period commencing at any time after the warrants become exercisable and ending on the third business day prior to the notice of redemption to warrant holders
CY2023	KACL	Shares Issuable Upon Conversion As Percentage On Shares Outstanding After Conversion SharesIssuableUponConversionAsPercentageOnSharesOutstandingAfterConversion	0.098	pure

Files In Submission

Name	View Source	Status
0001493152-23-034657-index-headers.html	Edgar Link	pending
0001493152-23-034657-index.html	Edgar Link	pending
0001493152-23-034657.txt	Edgar Link	pending
0001493152-23-034657-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_001.jpg	Edgar Link	pending
kacl-20230630.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
kacl-20230630_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
kacl-20230630_pre.xml	Edgar Link	unprocessable
kacl-20230630_lab.xml	Edgar Link	unprocessable
kacl-20230630_def.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$KACLF
Kairous Acquisition Corp. Ltd Stock $kaclf

2023 Q3 Form 10-K Financial Statement

#000149315223034657 Filed on September 28, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KACLF Kairous Acquisition Corp. Ltd Stock $kaclf

2023 Q3 Form 10-K Financial Statement

#000149315223034657 Filed on September 28, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KACLF
Kairous Acquisition Corp. Ltd Stock $kaclf